Clinical Trial

Permissive Versus Strict Intrapartum Glucose Management in Type 1 Diabetes (PRISM-T1D)

Study acronym: PRISM-T1D
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
PRISM-TID is a single center non-inferiority randomized controlled trial of permissive intrapartum glucose management (intervention) versus strict intrapartum glucose management (standard of care) among pregnant individuals with type 1 diabetes (T1D) using hybrid closed loop therapy (HCL) who are admitted for labor management. Participants will be randomized in a 1:1 fashion to one of two intrapartum glycemic control options: permissive (70-140 mg/dL) or strict (70-110 mg/dL). The primary aim of this trial it to demonstrate that permissive intrapartum glucose management is not associated with an increased risk of neonatal dysglycemia compared with strict intrapartum glucose management.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-12-17; most recent amendment 2026-04-28.
Status change: Not Yet Recruiting → Recruiting 2026-03-24
Trial Details
NCT Number NCT07293715
Lead Sponsor Ohio State University
Conditions Pregnancy, High Risk, Type 1 Diabetes
Enrollment 44 participants
Start Date 2026-02-25
Primary Completion 2027-06 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-04-29